Chief Executive Officer and founder, Mai-Britt Zocca, Ph.D.
Experienced biotech executive (15+y) having worked in a number of start-ups with significant insight into translational and clinical immune oncology.
Chief Medical Officer, Eva Ehrnrooth, M.D., Ph.D.
Board-certified oncologist who most recently served as executive director, the global clinical programme team leader at Boehringer Ingelheim. She held clinical development positions of increasing responsibility at Boehringer Ingelheim between 2010 and 2017. Previously Dr. Ehrnrooth was a medical director at Genmab and has been working as oncologist in the Department of Oncology at National Danish Hospital.
Chief Scientific Officer, , Dr. Muhammad Al-Hajj
Muhammad brings 18+ years of experience in Oncology drug discovery. He joined IO Biotech from Autolus Therapeutics, where he was Sr VP of Translational Sciences and played a key role in the progression of their CAR-T pipeline. Prior to that, he spent 12+ years in roles of increasing responsibilities leading R&D and Translational Medicine teams at Novartis (NIBR), GlaxoSmithKline & AstraZeneca contributing to the development of approved medicines. He is an inventor on 20+ patents and applications, and his peer-reviewed work has been cited over 15,000 times. He holds a PhD in Molecular Genetics, and completed post-doctoral training in Cancer/Stem Cells at the U of Michigan Cancer Center.
VP, Corporate Finance, Mikkel Dybkjaer, Ms.Econ.
+20 years of financial and strategic experience from pharma/biotech companies (e.g. Lundbeck and Genmab) and management consultancy companies (e.g. Accenture). Involved in multiple high value licensing deals/company acquisitions.
VP, Translational Research, Ayako Wakatsuki Pedersen, PhD
Experienced cancer immunologist (15+ years) with preclinical development of immunotherapeutic drugs in biotechs (8+ years).